Holen Sie sich die Stockscreener-App
12.82
1.54%
-0.20
Schlusskurs vom Vortag:
$13.02
Offen:
$13.27
24-Stunden-Volumen:
3.22M
Relative Volume:
1.28
Marktkapitalisierung:
$4.09B
Einnahmen:
$3.02B
Nettoeinkommen (Verlust:
$127.93M
KGV:
57.93
EPS:
0.2213
Netto-Cashflow:
$225.64M
1W Leistung:
-1.76%
1M Leistung:
+8.37%
6M Leistung:
+22.91%
1J Leistung:
+76.83%
1-Tages-Spanne:
$12.73
$13.85
1-Wochen-Bereich:
$12.73
$13.92
52-Wochen-Spanne:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.82 | 4.15B | 3.02B | 127.93M | 225.64M | 0.2213 |
TAK
Takeda Pharmaceutical Co Adr
|
16.60 | 53.90B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.52 | 49.70B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.36 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.22 | 36.43B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
574.29 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-04-22 - Seeking Alpha
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal - Reuters
AMRX News & Events - Intellectia AI
AMRX Should I Buy - Intellectia AI
4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy - Law360
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Sangri Today
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
AMRX: Acquisition establishes a US biosimilars leader, targeting $1–1.3B in biosimilar revenue by 2030 - TradingView
Kashiv BioSciences to be acquired by Amneal Pharmaceuticals - ROI-NJ
Amneal Pharmaceuticals to Acquire Kashiv BioSciences, Creating a Global Biosimilar Leader and Raising 2026 Financial Guidance - Minichart
Amneal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Amneal’s Bevacizumab Biosimilar Brochure Rebuked By FDA’s OPDP - Citeline News & Insights
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Benzinga
Amneal to acquire Kashiv BioSciences in biosimilar expansion By Investing.com - Investing.com South Africa
AMRX: Acquisition forms a global biosimilar leader, unlocking $300B+ opportunity and strong synergies - TradingView
Amneal to Acquire Kashiv, Expanding Biosimilars Platform - TipRanks
Shares of Amneal Pharmaceuticals, Inc. (AMRX) rose 3% in pre-market trading on Tuesday after the company announced two major positive developments: an upward revision of its adjusted profit forecast for 2024 and a strategic agreement to acquire Kashiv - Bitget
Amneal: Q1 Earnings Snapshot - marketscreener.com
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook (AMRX:NASDAQ) - Seeking Alpha
Amneal to Buy Kashiv BioSciences for $375M Cash, 28.9M Shares; Milestones Up to $350M - TradingView
(AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B$3.15B, vs. FactSet Est of $3.1B - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million - TradingView
Amneal Agrees to Acquire Kashiv BioSciences to Create - GlobeNewswire
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential (AMRX) - Seeking Alpha
Amneal’s Parkinson’s And Respiratory Moves Shift Focus To Complex Therapies - Yahoo Finance
How The Amneal Pharmaceuticals (AMRX) Story Is Evolving Around 2026 Guidance And US$17 Targets - Yahoo Finance
Amneal Pharmaceuticals stock (US03168L1052): Why Google Discover changes matter more now - AD HOC NEWS
Amneal reports positive interim data for Parkinson’s drug Crexont By Investing.com - Investing.com India
Amneal Pharmaceuticals Reports 'Positive' Interim Phase 4 Results for CREXONT in Parkinson's Disease - Moomoo
Amneal reports positive interim data for Parkinson’s drug Crexont - Investing.com
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily 'Good On” Time When Switching from RYTARY® - The Manila Times
Amneal Announces Additional Positive Interim Phase 4 - GlobeNewswire
Amneal rated Buy in new research coverage at UBS as growth pipeline expands (AMRX:NASDAQ) - Seeking Alpha
Healthcare Stocks Rise as Strait Reopening Cuts Costs | 2026 Market UpdateNews and Statistics - IndexBox
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to "Strong-Buy" at UBS Group - MarketBeat
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Does Amneal Pharmaceuticals' (AMRX) Inhaler Push Reveal a Durable Edge in Complex Generics? - Sahm
Market movers: Netflix, American Airlines, United Airlines, Amneal Pharmaceuticals... - Proactive financial news
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma - Yahoo! Finance Canada
UBS initiates Amneal Pharmaceuticals stock with buy rating at $19 - Investing.com
Amneal denied summary judgment against US states’ antitrust case over Phenytoin - MLex
Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit - Law360
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):